Log in to save to my catalogue

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2797147173

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Immunotherapy with chimeric antigen receptor (CAR)-expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma.
In an academic, phase 1-2 clinical trial, we enrolled patients (1 to 25 years of age) with relapsed or refractory, high-risk neuroblastoma in...

Alternative Titles

Full title

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2797147173

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2797147173

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2210859

How to access this item